Clinical trials: Peripheral T-cell Lymphomas, open to volunteers
Peripheral T-cell Lymphoma
BrEto-TCL - Defining the Role of Brentuximab and Etoposide for Optimizing First-line Therapy of T-cell Lymphomas
There is no data comparing the effectiveness of the 4 most relevant first-line therapy programs for peripheral T-cell lymphomas (CHOEP, CHOP, CHEP-BV, CHP-BV) in a single study.
- Trial name
- BrEto-TCL (NCT07258680)
- Testing
- Doxorubicin, Vincristine, Etoposide
- Volunteers
- 114 people
- Sponsor
- N.N. Petrov National Medical Research Center of Oncology
Acute Biphenotypic Leukemia, Acute Leukemia
Depletion of CD45RA Positive Naive T Cells for the Prevention of Graft Versus Host Disease in Older Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia or Myelodysplastic Syndrome
This phase II trial tests how well removing CD45RA positive naive T cells works to prevent graft versus host disease in older patients undergoing standard of care allogeneic hematopoietic stem cell transplantation for the…
- Conditions
- Acute Biphenotypic Leukemia, Acute Leukemia, Acute Leukemia of Ambiguous Lineage, Acute Lymphoblastic Leukemia
- Trial name
- NCT07819396
- Testing
- Allogeneic CD34+-enriched and CD45RA-depleted PBSCs, Biospecimen Collection, Bone Marrow Aspiration
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Fred Hutchinson Cancer Center
Peripheral T Cell Lymphoma
Combination Therapy With Tazemetostat in Relapsed and Refractory Peripheral T-cell Lymphoma
In decades, the outcome of patients with peripherial T-cell lymphomas is dismal, especially in relapsed or refractory population.
- Trial name
- NCT07209163
- Testing
- Tazemetostat, Linperlisib, Golidocitinib
- Volunteers
- 48 people
- Sponsor
- Ruijin Hospital
Previously Untreated Peripheral T-Cell Lymphoma
A Study of BEBT-908 in Combination With Chemotherapy in Patients With Previously Untreated Peripheral T-Cell Lymphoma (PTCL)
The goal of this clinical study is to find the best way to combine the study drug BEBT-908 (ifupinostat hydrochloride for injection) with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) for treating previously…
- Trial name
- NCT07676175
- Testing
- Ifupinostat Hydrochloride for Injection, Cyclophosphamide for Injection, Doxorubicin Hydrochloride for Injection
- Where
- 3 sites in China
- Volunteers
- 120 people
- Sponsor
- BeBetter Med Inc
Peripheral T Cells Lymphoma (PTCL)
Polyspecific Antibodies in Lymphoproliferative T-cell Disorders
This is a 2-part study consisting of a Part 1, dose escalation and dose-finding component to establish the Maximal Tolerated Dose (MTD), or Recommended Part 2 Dose (RP2D) of LIS1 as a single agent; followed by a Part 2, to…
- Trial name
- PALT1 (NCT06495723)
- Testing
- LIS1
- Where
- 8 sites in France, Italy
- Volunteers
- 54 people
- Sponsor
- Xenothera SAS
PTCL, First Line Treatment
SHR2554 Plus Liposomal Mitoxantrone as First-line Treatment for Peripheral T-cell Lymphoma (PTCL)
This is a single-arm, multicenter, Phase Ib/IIa study designed to explore the efficacy and safety of SHR2554 in combination with liposomal mitoxantrone for the treatment of patients with treatment-naive peripheral T-cell lymphoma…
- Trial name
- NCT07725705
- Testing
- SHR2554 combined with Liposomal Mitoxantrone
- Volunteers
- 44 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Angioimmunoblastic T-cell Lymphoma, Enteropathy-Associated T-Cell Lymphoma
Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma
This phase II trial studies the effect of duvelisib or CC-486 and usual chemotherapy consisting of cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone in treating patients with peripheral T-cell lymphoma.
- Conditions
- Angioimmunoblastic T-cell Lymphoma, Enteropathy-Associated T-Cell Lymphoma, Follicular T-Cell Lymphoma, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma
- Trial name
- NCT04803201
- Testing
- Cyclophosphamide, Doxorubicin, Vincristine
- Where
- 96 sites in United States
- Volunteers
- 170 people
- Sponsor
- Alliance for Clinical Trials in Oncology
PTCL
Randomized Phase IIB Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in PTCL
The purpose of this study is to find out whether the combination treatment of romidepsin and oral azacytidine is safe and effective in patients with Peripheral T-Cell Lymphoma (PTCL).
- Trial name
- PTCL (NCT04747236)
- Testing
- Azacytidine, Romidepsin, Belinostat
- Where
- 6 sites in United States
- Volunteers
- 50 people
- Sponsor
- University of Virginia
Relapsed Peripheral T-Cell Lymphoma, Refractory Peripheral T-Cell Lymphoma
Pralatrexate Combined With Chidamide Bridging Allogeneic HSCT for Refractory/Relapsed Peripheral T-cell Lymphoma
This is a multicenter, prospective study of Pralatrexate combined with Chidamide bridging Allogeneic Hematopoietic Stem Cell Transplantation for Refractory/Relapsed Peripheral T-cell Lymphoma
- Trial name
- NCT06671717
- Testing
- Pralatrexate combined with Chidamide bridging Allogeneic Hematopoietic Stem Cell Transplantation
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Peking University People's Hospital
Peripheral T-Cell Lymphoma, Not Classified
Golidocitinib With Azacitidine and Chidamide in Patients With Peripheral T-cell Lymphoma.
In decades, the outcome of patients with peripherial T-cell lymphomas is dismal, especially in relapsed or refractory population.
- Trial name
- NCT07081607
- Testing
- golidocitinib with azacytidine and chidamide
- Volunteers
- 30 people
- Sponsor
- Ruijin Hospital
Diffuse Large B-Cell Lymphoma (DLBCL), Hodgkin Lymphoma
Autologous IC-Nine, CD30 CAR, and Constitutive IL7R Expressing EBVST for CD30 Lymphoma (ANCILE-30)
This Phase I study will evaluate the safety of autologous Epstein-Barr virus-specific T lymphocytes modified to express a constitutively active IL7 receptor (C7R) and a chimeric antigen receptor (CAR) for CD30…
- Conditions
- Diffuse Large B-Cell Lymphoma (DLBCL), Hodgkin Lymphoma, Peripheral T-cell Lymphoma (PTCL), Anaplastic Large Cell Lymphoma, ALK-Positive
- Trial name
- ANCILE-30 (NCT07729397)
- Testing
- Autologous C7R.CD30-CAR-EBVSTs
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- The Methodist Hospital Research Institute
Peripheral T Cell Lymphoma, Relapsed Peripheral T-Cell Lymphoma
Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma
This phase I trial studies the best dose and side effects of recombinant vesicular stomatitis virus (VSV) carrying the human (h) sodium iodide symporter (NIS) and Interferon (IFN) beta (β) genes (VSV-hIFNβ-NIS) in combination…
- Conditions
- Peripheral T Cell Lymphoma, Relapsed Peripheral T-Cell Lymphoma, Peripheral T-Cell Lymphoma, Not Otherwise Specified, Anaplastic Large Cell Lymphoma
- Trial name
- NCT06508463
- Testing
- Biopsy, Biospecimen Collection, Bone Marrow Biopsy
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- Mayo Clinic
Newly Diagnosed Peripheral T-cell Lymphoma
A Randomized Clinical Trial Comparing Chi-BEAM With BEAM Regimen Combined With ASCT for the Treatment of ND PTCL
The goal of this clinical trial is to compare Chi-BEAM With BEAM Regimen Combined With ASCT for the Treatment of ND PTCL. The main question it aims to answer are: •Whether Chi-BEAM improves patient survival compared to BEAM group…
- Trial name
- NCT05931263
- Testing
- C-BEAM Regimen, BEAM Regimen
- Where
- China
- Volunteers
- 104 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Peripheral T-cell Lymphoma
Linperlisib Combined With Chidamide in Patients With PTCL
The phase Ib part of this study aims to determine the recommended phase II dose （RP2D）of linperlisib in combination with chidamide for the treatment of peripheral T-cell lymphoma (PTCL).
- Trial name
- NCT06421948
- Testing
- Linperlisib and chidamide, cyclophosphamide, doxorubicin/epirubicin, vincristine, and prednisone
- Where
- 6 sites in China
- Volunteers
- 134 people
- Sponsor
- Yanyan Liu
Relapsed/Refractory Peripheral T Cell Lymphoma
To Evaluate XNW5004 Tablets in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma
This is an open-label, multi-center clinical study to evaluate the efficacy and safety of XNW5004 tablets in subjects with R/R PTCL. The study plans to enroll approximately 50 subjects.
- Trial name
- NCT06702605
- Testing
- XNW5004 tablets
- Volunteers
- 50 people
- Sponsor
- Evopoint Biosciences Inc.
Lymphoma
A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype
The study will evaluate the progression-free survival benefit of duvelisib monotherapy as compared to investigator's choice of gemcitabine or bendamustine in participants with relapsed/refractory nodal T cell lymphoma with TFH…
- Trial name
- TERZO (NCT06522737)
- Testing
- Duvelisib, Gemcitabine, Bendamustine
- Where
- 44 sites in Belgium, Czechia and 8 more
- Volunteers
- 124 people
- Sponsor
- SecuraBio
Haematological Malignancy, Malignant Neoplasm
DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers
This clinical trial is looking at a drug called alectinib. Alectinib is approved as standard of care treatment for adult patients with certain types of lung cancer.
- Conditions
- Haematological Malignancy, Malignant Neoplasm, Lymphoproliferative Disorders, Neoplasms by Histologic Type
- Trial name
- DETERMINE (NCT05770037)
- Testing
- Alectinib
- Where
- 27 sites in United Kingdom
- Volunteers
- 30 people
- Sponsor
- Cancer Research UK
Acute Leukemia, Acute Lymphoblastic Leukemia
Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)
This phase II trial investigates two strategies and how well they work for the reduction of graft versus host disease in patients with acute leukemia or MDS in remission.
- Conditions
- Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT03970096
- Testing
- Total-Body Irradiation, Thiotepa, Fludarabine
- Where
- 3 sites in United States
- Volunteers
- 120 people
- Sponsor
- Fred Hutchinson Cancer Center
Peripheral T Cell Lymphoma
Genotype-guided Treatment in Newly Diagnosed PTCL
This study includes Phase I and Phase II stages. Phase I is an open-label trial to confirm RP2D of oral targeted agents in three genetic subtypes.
- Trial name
- THEORY (NCT05675813)
- Testing
- CHOP+selinexor+5-Azacitidine, CHOP+duvelisib+5-Azacitidine, CHOP+chidamide+tislelizumab
- Where
- China
- Volunteers
- 264 people
- Sponsor
- Ruijin Hospital
Relapsed Peripheral T-Cell Lymphoma, Refractory Peripheral T-Cell Lymphoma
Pembrolizumab and Olaparib Treatment for Relapsed or Refractory Peripheral T-Cell Lymphoma
The goal of this clinical trial is to evaluate the efficacy and safety of Pembrolizumab in combination with Olaparib in participants with relapsed/refractory Peripheral T-cell Lymphoma (PTCL).
- Trial name
- POLAR (NCT06160843)
- Testing
- Pembrolizumab IV infusion Q3W, with daily oral Olaparib.
- Where
- Singapore
- Volunteers
- 24 people
- Sponsor
- National Cancer Centre, Singapore